|Click on "►" to expand:|
Topical Eflornithine slows down the growth of hair through its effect on a specific enzyme (a protein in the body involved in the production of hair). It is used to reduce the growth of excessive hair (Hirsutism) on the face of women older than 18 years of age.
 BRAND NAMES
- International: Vaniqa
- Italy: Vaniqa crema al 11,5% Riassunto EMA, monografia
- Lebanon: Vaniqa 11.5%, FLOREXA 11.5%
 MECHANISM OF ACTION
Topical eflornithine, works by blocking the action of an enzyme called ornithine decarboxylase. This enzyme is found in the bulb of the hair follicle where it controls hair production. When this enzyme is blocked, the growth of hair is slowed down.
Topical Eflornithine is used for the treatment of facial hirsutism in women. Facial hirsutism is excessive growth on the face of coarse hair, often in a male pattern.
Topical Eflornithine is applied to clean and dry affected areas of the face and under the chin twice a day (at least eight hours apart). It is applied in a thin layer and rubbed in thoroughly. Improvements may be noticed within eight weeks of starting treatment. Continued treatment is needed to maintain the beneficial effects and may lead to further improvement. Topical Eflornithine should be stopped if no improvements are noticed within four months of starting treatment.
Hypersensitivity to eflornithine
 WARNINGS AND PRECAUTIONS
Excessive hair growth can result from serious underlying disorders (e.g. polycystic ovary syndrome, androgen secreting neoplasm) or certain active substances (e.g. cyclosporin, glucocorticoids, minoxidil, phenobarbitone, phenytoin, combined estrogen-androgen hormone replacement therapy). These factors should be considered in the overall medical treatment of patients who might be prescribed Eflornithine topical cream.
No interaction studies have been performed.
 PREGNANCY AND LACTATION
- Pregnancy Category C (US). Animal studies have shown reproductive toxicity. The potential risk to humans is unknown. Therefore, women who are pregnant or planning pregnancy should use an alternative means to manage facial hair.
- Breastfeeding: It is not known if eflornithine is excreted in human milk. Women should not use topical eflornithine whilst breastfeeding.
 SIDE EFFECTS
The most common side effect with Topical Eflornithine (seen in more than 1 patient in 10) is acne.
Transient stinging or burning may also occur when the cream is applied to abraded or broken skin.
 RELATED LINKS